Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

$SAGE
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $SAGE alert in real time by email

Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates.

The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.

Get the next $SAGE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SAGE

DatePrice TargetRatingAnalyst
3/11/2025$5.00Underperform
BofA Securities
11/21/2024$4.00Underperform → Sector Perform
RBC Capital Mkts
10/10/2024Mkt Perform
Raymond James
10/4/2024$10.00 → $4.00Outperform → Sector Perform
RBC Capital Mkts
7/30/2024$16.00 → $10.00Buy → Hold
TD Cowen
7/25/2024$18.00 → $12.00Overweight → Neutral
JP Morgan
5/29/2024$15.00Neutral
Robert W. Baird
5/29/2024$8.00Sell
Citigroup
More analyst ratings

$SAGE
Press Releases

Fastest customizable press release news feed in the world

See more
  • Sage Therapeutics Announces R&D Leadership Transition

    Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

    Strong first full year of launch with sustained growth in shipments to women with postpartum depression; Nearly 2,500 shipments in fourth quarter of 2024 (21% increase from third quarter) $11.4 million in ZURZUVAE® (zuranolone) collaboration revenue in the fourth quarter of 2024 and $36.1 million for the year ended December 31, 2024 (50% of the net revenues recorded by Biogen) Cash, cash equivalents, and marketable securities of $504 million as of December 31, 2024; Cash runway expected to support operations to mid-2027 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We are

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

    Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-appr

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SAGE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SAGE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SAGE
SEC Filings

See more

$SAGE
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

    For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SAGE
Leadership Updates

Live Leadership Updates

See more
  • Sage Therapeutics Announces R&D Leadership Transition

    Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sage Therapeutics Appoints Jessica Federer to Board of Directors

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005117/en/Jessica Federer (Photo: Business Wire) "We are thrilled to have Jessica join our Board of Directors. Jessica is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Jessica's innate curiosit

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer

    Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage's current and emerging product pipeline through all stages of development. "We are thrilled to have Dr. Gault join Sage to lead the development and delivery of our pipeline of potential new medicines and be a partner in our mission to improve the lives of people affected by brain health disorders," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Dr. Gault's vision, experience and deep commitment to this field of med

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SAGE
Financials

Live finance-specific insights

See more
  • Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

    Strong first full year of launch with sustained growth in shipments to women with postpartum depression; Nearly 2,500 shipments in fourth quarter of 2024 (21% increase from third quarter) $11.4 million in ZURZUVAE® (zuranolone) collaboration revenue in the fourth quarter of 2024 and $36.1 million for the year ended December 31, 2024 (50% of the net revenues recorded by Biogen) Cash, cash equivalents, and marketable securities of $504 million as of December 31, 2024; Cash runway expected to support operations to mid-2027 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We are

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

    Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-appr

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

    Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarter Sage and Biogen will not pursue further development of zuranolone in major depressive disorder (MDD) in the U.S. Topline data from the DIMENSION Study in Huntington's Disease (HD) expected late 2024 Cash, cash equivalents and marketable securities of $569 million as of September 30, 2024 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024. "We are committed to harnessing the full potential of ZURZUVAE as

    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SAGE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more